Managing the risk of venous thromboembolism in transgender adults undergoing hormone therapy

References

• Gomes MPV, Deitcher SR. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. Arch Intern Med. 2004;164(18):1965. doi:10.1001/archinte.164.18.196515477430
   PubMedGoogle Scholar
• Hess J, Breidenstein A, Henkel A, et al. Satisfaction, quality of life and psychosocial resources of male to female transgender after gender reassignment surgery. Eur Urol Suppl. 2018;17(2):e1748. doi:10.1016/S1569-9056(18)32062-1
   Google Scholar
• S. E. James, et al. The report of the 2015 U.S. Transgenderr Survey. National Center for Transgnder Equality; 2016 Available from: https://transequality.org/sites/default/files/docs/usts/USTS-Full-Report-Dec17.pdf. Accessed June 10, 2019.
   Google Scholar
• Heylens, Gunter, Verroken C, De Cock S, T'Sjoen G, De Cuypere G. Effects of different steps in gender reassignment therapy on psychopathology: a prospective study of persons with a gender identity disorder. J Sex Med. 2014;11(1):119–126.24344788
   PubMed Web of Science ®Google Scholar
• Wierckx K, Elaut E, Declercq E, et al. Prevalence of cardiovascular disease and cancer during cross-sex hormone therapy in a large cohort of trans persons: a case–control study. Eur J Endocrinol. 2013;169(no. 4):471–478. doi:10.1530/EJE-13-049323904280
   PubMed Web of Science ®Google Scholar
• Asscheman H, Giltay EJ, Megens JAJ, de Ronde W, van Trotsenburg MAA, Gooren LJG. A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol. 2011;164(4):635–642. doi:10.1530/EJE-10-103821266549
   PubMed Web of Science ®Google Scholar
• Getahun D, Nash R, Flanders WD, et al. Cross-sex hormones and acute cardiovascular events in transgender persons: a cohort study. Ann Intern Med. 2018;169:205. doi:10.7326/M17-278529987313
   PubMed Web of Science ®Google Scholar
• van Kesteren PJM, Asscheman H, Megens JAJ, Gooren LJG. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol (Oxf). 1997;47(3):337–343. doi:10.1046/j.1365-2265.1997.2601068.x9373456
   PubMed Web of Science ®Google Scholar
• Asscheman, Asscheman H, Giltay EJ, et al. A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol. 2011;164:635–642. doi:10.1530/EJE-10-103821266549
   PubMed Web of Science ®Google Scholar
• Tyler ET. Oral contraception and venous thrombosis. JAMA. 1963;185(2):131. doi:10.1001/jama.1963.03060020091034
   Web of Science ®Google Scholar
• American College of Obstetricians and Gynecologists. Risk of venous thromboembolism among users of drospirenone-containing oral contraceptive pills. Committee Opinion No. 540. Obstetrics Gynecol. 2012;120:1239–1242.
   Google Scholar
• Vandenbroucke JP, Koster T, Rosendaal FR, Briët E, Reitsma PH, Bertina RM. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994;344(8935):1453–1457. doi:10.1016/S0140-6736(94)90286-07968118
   PubMed Web of Science ®Google Scholar
• Sidney S, Cheetham TC, Connell FA, et al. Recent combined hormonal contraceptives (CHCs) and the risk of thromboembolism and other cardiovascular events in new users. Contraception. 2013;87(1):93–100. doi:10.1016/j.contraception.2012.09.01523083525
   PubMed Web of Science ®Google Scholar
• Le Moigne E, Tromeur C, Delluc A, et al. Risk of recurrent venous thromboembolism on progestin-only contraception: a cohort study. Haematologica. 2016;101(1):e12–e14. doi:10.3324/haematol.2015.13488226452982
   PubMed Web of Science ®Google Scholar
• FDA drug safety communication: updated information about the risk of blood clots in women taking birth control pills containing drospirenone. UCM (US Food and Drug Administration). Available from: https://www.fda.gov/Drugs/DrugSafety/ucm299305. Accessed December 3, 2018.
   Google Scholar
• Vandenbroucke JP, Helmerhorst FM, Bloemenkamp KWM, Rosendaal FR. Third-generation oral contraceptive and deep venous thrombosis: from epidemiologic controversy to new insight in coagulation. Am J Obstet Gynecol. 1997;177(4):887–891. doi:10.1016/S0002-9378(97)70289-89369840
   PubMed Web of Science ®Google Scholar
• Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994;344(8935):1453–1457
   Google Scholar
• O. Lidegaard, et al. Hormonal contraception and risk of venous thromboembolism: national Follow-up Study. Bmj. 2009;339(aug 13 2):b2890–b2890. doi:10.1136/bmj.b289019679613
   PubMed Web of Science ®Google Scholar
• Ducros E, Berthaut A, Mirshahi SS, et al. Aldosterone modifies hemostasis via upregulation of the protein-c receptor in human vascular endothelium. Biochem Biophys Res Commun. 2008;373(2):192–196. doi:10.1016/j.bbrc.2008.05.18518555797
   PubMed Web of Science ®Google Scholar
• FDA drug safety communication: updated information about the risk of blood clots in women taking birth control pills containing drospirenone. UCM (US Food and Drug Administration). Available from: https://www.fda.gov/Drugs/DrugSafety/ucm299305. Accessed December 3, 2018.
   Google Scholar
• Seeger JD, Loughlin J, Eng PM, Clifford CR, Cutone J, Walker AM. Risk of thromboembolism in women taking Ethinylestradiol/Drospirenone and other oral contraceptives. Obstetrics Gynecol. 2007;110(3):587–593. doi:10.1097/01.AOG.0000279448.62221.a8
   PubMed Web of Science ®Google Scholar
• Dinger J, Do Minh T, Buttmann N, Bardenheuer K. Effectiveness of oral contraceptive pills in a large US cohort comparing progestogen and regimen. Obstetrics Gynecol. 2011;117(1):33–40. doi:10.1097/AOG.0b013e31820095a2
   PubMed Web of Science ®Google Scholar
• World Health Organization. Combined hormonal contraceptive use during the postpartum period. January 26, 2010. Available from:  https://apps.who.int/iris/bitstream/handle/10665/70447/WHO_RHR_10.15_eng.pdf;jsessionid=A2053BAFEA3D15DF51D82559E9973599?sequence=1. Accessed June 10, 2019.
   Google Scholar
• Jackson E, Curtis KM, Gaffield ME. Risk of venous thromboembolism during the postpartum period: a systematic review. Obstetrics Gynecol. 2011;117:691–703. doi:10.1097/AOG.0b013e31820ce2db
   PubMed Web of Science ®Google Scholar
• Parker-Pope T, The women’s health initiative and the body politic. The New York Times. 2011 4 9.
   Google Scholar
• Burwen DR, Wu C, Cirillo D, et al. Venous thromboembolism incidence, recurrence, and mortality based on women’s health initiative data and medicare claims. Thromb Res. 2017;150:78–85. doi:10.1016/j.thromres.2016.11.01528063368
   PubMed Web of Science ®Google Scholar
• Canonico M, Plu-Bureau G, O’Sullivan MJ, et al. Age at menopause, reproductive history, and venous thromboembolism risk among postmenopausal women: the women’s health initiative hormone therapy clinical trials. Menopause. 2014;21(3):214–220. doi:10.1097/GME.0b013e31829752e023760439
   PubMed Web of Science ®Google Scholar
• Curb JD, Ross LP, Bray PF, et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med. 2006;166(7):772–780. doi:10.1001/archinte.166.7.77216606815
   PubMedGoogle Scholar
• Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007;115(7):840–845. doi:10.1161/CIRCULATIONAHA.106.64228017309934
   PubMed Web of Science ®Google Scholar
• Conard J. Biological coagulation findings in third-generation oral contraceptives. Hum Reprod Update. 1999;5(6):672–680. doi:10.1093/humupd/5.6.67210652977
   PubMed Web of Science ®Google Scholar
• Oger E, Alhenc-Gelas M, Lacut K, et al. Differential effects of oral and transdermal Estrogen/Progesterone regimens on sensitivity to activated Protein C among postmenopausal women: a randomized trial. Arterioscler Thromb Vasc Biol. 2003;23(9):1671–1676. doi:10.1161/01.ATV.0000087141.05044.1F12869355
   PubMed Web of Science ®Google Scholar
• Deguchi H, Bouma BN, Middeldorp S, Lee YM, Griffin JH. Decreased plasma sensitivity to activated protein c by oral contraceptives is associated with decreases in plasma glucosylceramide. JTH. 2005;3(5):935–938. doi:10.1111/j.1538-7836.2005.01335.x15869587
   PubMed Web of Science ®Google Scholar
• Getahun D, Nash R, Flanders WD, et al. Cross-sex hormones and acute cardiovascular events in transgender persons: a cohort study. Ann Intern Med. 2018;169:205–213. doi:10.7326/M17-278529987313
   PubMed Web of Science ®Google Scholar
• Wierckx K, Mueller S, Weyers S, et al. Long‐term evaluation of cross‐sex hormone treatment in transsexual persons. J Sex Med. 2012;9(10):2641–2651. doi:10.1111/j.1743-6109.2012.02876.x22906135
   PubMed Web of Science ®Google Scholar
• Seal LJ, Franklin S, Richards C, Shishkareva A, Sinclaire C, Barrett J. Predictive markers for mammoplasty and a comparison of side effect profiles in transwomen taking various hormonal regimens. J Clin Endocrinol Metab. 2012;97(12):4422–4428. doi:10.1210/jc.2012-203023055547
   PubMed Web of Science ®Google Scholar
• Ott J, Kaufmann U, Bentz E-K, Huber JC, Tempfer CB. Incidence of thrombophilia and venous thrombosis in transsexuals under cross-sex hormone therapy. Fertil Steril. 2010;93(4):1267–1272. doi:10.1016/j.fertnstert.2008.12.01719200981
   PubMed Web of Science ®Google Scholar
• Wilson R, Spiers A, Ewan J, Johnson P, Jenkins C, Carr S. Effects of high dose oestrogen therapy on circulating inflammatory markers. Maturitas. 2009;62(3):281–286. doi:10.1016/j.maturitas.2009.01.00919231116
   PubMed Web of Science ®Google Scholar
• Lowe GDO. Hormone replacement therapy and cardiovascular disease: increased risks of venous thromboembolism and stroke, and no protection from coronary heart disease. J Intern Med. 2004;256(5):361–374. doi:10.1111/j.1365-2796.2004.01400.x15485471
   PubMed Web of Science ®Google Scholar
• Vongpatanasin W, Tuncel M, Wang Z, Arbique D, Mehrad B, Jialal I. Differential Effects of Oral versus Transdermal Estrogen Replacement Therapy on C-Reactive Protein in Postmenopausal Women. J Am Coll Cardiol. 2003;41(8):1358–1363. doi:10.1016/S0735-1097(03)00156-612706932
   PubMed Web of Science ®Google Scholar
• Arnold JD, Sarkodie EP, Coleman ME, Goldstein DA. Incidence of venous thromboembolism in transgender women receiving oral estradiol. J Sex Med. 2016;13(11):1773–1777. doi:10.1016/j.jsxm.2016.09.00127671969
   PubMed Web of Science ®Google Scholar
• Khan J, Schmidt RL, Spittal MJ, Goldstein Z, Smock KJ, Greene DN. Venous thrombotic risk in transgender women undergoing estrogen therapy: a systematic review and meta-analysis. Clin Chem. 2019;65(1):57–66.
   Web of Science ®Google Scholar
• Defreyne J, Van de Bruaene LDL, Rietzschel E, Van Schuylenbergh J, T’Sjoen GGR. Effects of gender-affirming hormones on lipid, metabolic, and cardiac surrogate blood markers in transgender persons. Clin Chem. 2019;65(1):119–134. doi:10.1373/clinchem.2018.28824130602477
   PubMed Web of Science ®Google Scholar